MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

UPDRS III score and RS latency can determine the possible neuromodulative role of STN DBS in Parkinson’s disease (PD) patients

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

Meeting: 2017 International Congress

Abstract Number: 374

Keywords: Deep brain stimulation (DBS), Eye movement, Parkinsonism

Session Information

Date: Monday, June 5, 2017

Session Title: Surgical Therapy: Parkinson’s Disease

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: The aim of this study was to evaluate the impact of STN DBS on the changes of UPDRS scale and RS parameters (OFF phase) in 3 PD groups: early-DBS STN (DBS-group), late-DBS STN (POP-group) and one that obtained only medication therapy (MED-group).

Background: Subthalamic nucleus deep brain stimulation (STN DBS) has been claimed to change the progression in animal models, but there are lacking information about the possible neuromodulative role of STN DBS in humans.  

Methods: DBS-group consisted of 20 PD patients (7F,13M) who underwent bilateral STN DBS. POP-group consisted of 15 post-DBS PD patients (6F,9M) in median 24 month-time after surgery. Control group (MED-group) consisted of 24 patients (13F,11M) who did not underwent surgical intervention. UPDRS III scale and RS parameters (latency, amplitude, duration, peak of velocity) were measured during 3 visits (V1, V2, V3) in total OFF phase. The mean period between visits was 9±3months.

Results: We have observed the comparable UPDRS III gain in V3/V2/V1 MED-group and POP-group (p<0,05) but not V3/V2 (p>0,05) vs V2/V1 (p<0,05) DBS-group. There was also interesting relation between RS latency and DBS treatment: the only change in V2/V1 DBS-group vs no change in MED-group and POP-group (p>0,05).

Conclusions: The strongest effect of STN DBS on RS parameters was during first 6 postoperative months whereas the most influential effect of STN DBS treatment on UPDRS III OFF score was observed during 6-12 months after surgery (but not in longer post-DBS periods).   

References: Partially supported by grant: NCN Dec-2011/03/B/ST6/03816.

To cite this abstract in AMA style:

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski. UPDRS III score and RS latency can determine the possible neuromodulative role of STN DBS in Parkinson’s disease (PD) patients [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/updrs-iii-score-and-rs-latency-can-determine-the-possible-neuromodulative-role-of-stn-dbs-in-parkinsons-disease-pd-patients/. Accessed June 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/updrs-iii-score-and-rs-latency-can-determine-the-possible-neuromodulative-role-of-stn-dbs-in-parkinsons-disease-pd-patients/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley